ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allysta Pharmaceutical
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Dry eye disease for > 3 months meeting specific sign and symptom criteria

• Best corrected visual acuity of +0.6 logMAR or better

• Willing to sign informed consent and attend study visits

• Willing to comply with contraception requirements

Exclusion Criteria:

• Unable to meet specific sign and symptom criteria

• Signs of ophthalmic allergic, inflammatory or infection conditions

• Use of contact lenses

• Anatomic abnormalities preventing accurate study assessments

• Use of medications that influence eye dryness

• Recent ophthalmic surgery

• Unwilling to suspend current treatments for dry eye disease